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Thomas A. Ratko,8 Donna Wall,9 Philip L. McCarthy, Jr.,1 Theresa Hahn1Clinical research published since the first evidence-based review on the role of hematopoietic stem cell
transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and crit-
ically evaluated in this update. Treatment recommendations are provided by an expert panel. Allogeneic SCT
is recommended for children who: are in second complete remission (CR2) after experiencing an early mar-
row relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1;
have T-lineage ALL in CR2; or have ALL in third or greater remission. Although the 2005 pediatric ALL
evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome pos-
itive (Ph1) ALL in CR1, preliminary tyrosine kinase inhibitor (TKI) data demonstrate that early outcomes are
comparable for allogeneic SCTand chemotherapy1 imatinib. Based on the evidence, autologous SCT is not
recommended for ALL in CR1. Allogeneic SCT is not recommended for: T-lineage ALL in CR1; mixed-lineage
leukemia (MLL)1 ALL when it is the sole adverse risk factor; isolated central nervous system (CNS) relapse
in precursor-B ALL. Based on expert opinion, allogeneic SCT may be considered for hypodiploid ALL and
persistent matched related donor (MRD) positivity in ALL in CR1 or greater, although these are areas
that need further study. Treatment recommendations pertaining to various transplantation techniques are
also provided, as are areas of needed future research.
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6/j.bbmt.2011.12.585ment of systematic evidence-based reviews (EBRs)
and position statements on the effectiveness of autolo-
gous and allogeneic hematopoietic stem cell transplan-
tation (SCT) for specific diseases. In 2009, the
ASBMT EBR Steering Committee determined that
previously published reviews should be updated regu-
larly at approximately 5-year intervals. This consti-
tutes the update of the pediatric acute lymphoblastic
leukemia (ALL) EBR originally published in 2005.UPDATE OF THE PEDIATRIC ALL EBR
This pediatric ALL EBR update adheres to the
methodology and grading systems presented in
Appendix A (online only). In the original pediatric
ALL EBR [1], each article was summarized in detail
in the text, accompanied by summary tables comparing
study designs and patient outcomes. To streamline this
update, a concise summary of outcomes is provided in
each section of text, whereas descriptions of the study
design, patient population, and clinical outcomes of505
506 Biol Blood Marrow Transplant 18:505-522, 2012D. M. Oliansky et al.each article are presented in summary tables. There-
fore, the reader is urged to refer to the primary studies
for additional details.
Evidence in each section is presented with the
highest quality studies first and the studies of equal
quality are presented in descending order by study
population size. New evidence is provided first in
each table, followed by the highest quality studies (rat-
ings from 111 to 211) used to make treatment rec-
ommendations in the original pediatric ALL EBR.
Level 1 and level 2 evidence is presented in the tables
for each study that provided biologic assignment
(donor versus no donor) and randomized (autologous
SCT versus chemotherapy) results.TREATMENT RECOMMENDATIONS
Table 1 contains the summary of consensus treat-
ment recommendations made by the expert panel
based on the summarized evidence on the use of
SCT to treat pediatric ALL. The consensus process
is detailed in Appendix A (online only) and involves
a teleconference during which panelists critically dis-
cuss the evidence for each section of the review and de-
velop treatment recommendations rated according to
the categories in Appendix A, Table 2.
The new treatment recommendations are based on
the pediatric ALL evidence published from January
2005 through October 15, 2010. In addition, the treat-
ment recommendations from the original pediatric
ALL EBR are incorporated into the respective tables
when applicable. It is indicated whether new evidence
strengthens, modifies, or does not change the original
recommendation.TRANSPLANTATION VERSUS
CHEMOTHERAPY FOR PEDIATRIC ALL
Published since the original pediatric ALL EBR,
and briefly summarized in the text, are 13 studies com-
paring transplantation versus chemotherapy as treat-
ment for pediatric patients (\18 years) with ALL in
first morphologic complete remission (CR1; n 5 6
studies) or in $ second complete remission (CR2) or
relapsed disease (n 5 7 studies).
Transplantation versus Chemotherapy for
Pediatric ALL in CR1
Table 2 presents a detailed summary of the study
designs, patient populations, and outcomes from the
6 new studies of patients in CR1, as well as four high
quality (211) studies comparing transplantation
versus chemotherapy in CR1 that were used to make
treatment recommendations in the original pediatric
ALL EBR. The quality rating (Appendix A; Table 1)
of these studies ranged from 11 to 21.The prospective, multicenter, Programa para el
Estudio de la Terapeutica enHemopatıaMaligna (PE-
THEMA) ALL-93 trial by Ribera et al. [2] reported no
significant differences in 5-year disease-free survival
(DFS) or overall survival (OS) between patients with
very high-risk ALL in CR1 who were randomized to
autologous SCT versus chemotherapy or for patients
who had a donor (allogeneic SCT) versus those who
did not (chemotherapy or autologous SCT).
A retrospective analysis by Arico et al. [3] reported
a significant improvement in 5-year DFS and OS for
patients with Philadelphia chromosome positive
(Ph1) ALL in CR1 who underwent any SCT
(matched related donor [MRD], matched unrelated
donor [MUD], or mismatched related donor
[MMRD] allogeneic SCT or autologous SCT) versus
those who received only chemotherapy with no tyro-
sine kinase inhibitor (TKI) therapy.
A prospective, collaborative group study by Bal-
duzzi et al. [4], reported a significant improvement in
5-year DFS, but not OS, for very high-risk pediatric
patients with ALL in CR1 who had a donor versus
those who did not, including those who had primary
induction failure, and also for those who underwent
a MRD or MUD allogeneic SCT versus those who
received chemotherapy only.
Mann et al. [5] provided a retrospective analysis of
infants (#1 year) with mixed-lineage leukemia
(MLL)1 ALL from the collaborative group study
Interfant-99 trial, who underwent an HLA-MRD or
HLA-mismatched unrelated donor (MMUD) alloge-
neic SCT versus chemotherapy alone. A significant
benefit in 5-year DFS and OS for allogeneic SCT
was reported, but only for patients with high-risk
MLL1with additional poor prognostic characteristics
versus those with MLL positivity alone.
In a retrospective analysis of the ALL-Berlin-
Frankfurt-M€unster (BFM)-90 and 95 trials, Schrauder
et al. [6] reported a significant improvement in 5-year
DFS and OS with allogeneic bone marrow transplan-
tation (BMT) versus chemotherapy in pediatric
patients with very high-risk T ALL in CR1.
The prospective, multicenter, Children’s Oncol-
ogy Group (COG) AALL0031 trial by Schultz et al.
[7] reported no significant difference in 3-year event-
free survival (EFS) among very high-risk pediatric pa-
tients with Ph1 ALL in CR1 who received imatinib
therapy with an intensive chemotherapy regimen fol-
lowed by a matched sibling allogeneic BMT, alterna-
tive donor allogeneic SCT, or chemotherapy plus
imatinib maintenance without SCT.
There were 4 high-quality (211) studies in the
original pediatric ALL EBR used to make a treatment
recommendation about the use of transplantation
versus chemotherapy to treat pediatric ALL in CR1.
Arico et al. [8] reported significantly better 5-year
EFS and OS for high-risk pediatric patients with
Table 1. Summary of Updated Treatment Recommendations for Pediatric ALL
Indication for SCT Original vs New Rec
Tx Rec
Grade*
Highest Level
of Evidence† Ref. No.‡ Treatment Recommendation Comments
TRANSPLANTATION VS CHEMOTHERAPY FOR PEDIATRIC ALL
Autologous SCT vs chemotherapy in first morphologic
complete remission
New treatment recommendation based on
new evidence
B 1+ 2 Autologous SCT is not recommended in CR1, nor is it a usual
practice in children.
Allogeneic SCT vs Chemotherapy in First Morphologic Complete Remission
Ph+ ALL New evidence changed the original
recommendation
B 2+ 7 In the 2005 EBR, there was a clear advantage for allogeneic SCT for
Ph+ ALL in CR1 before the availability of TKI therapy. New, but
preliminary, TKI data presented in one small study in this update
demonstrate that early outcomes are comparable between
allogeneic SCTand intensive chemotherapy with imatinib. Further
study is needed to determine whether imatinib and intensive
chemotherapy should replace SCT for some or all patients with
Ph+ ALL. Moreover, the role of long-term TKI use is not known.
This is an evolving field in need of further study.
T-ALL New treatment recommendation based on
new evidence
C 2+ 6 While there are limited data to make a recommendation, based on
expert opinion allogeneic SCT may be considered. One study
showed a benefit for SCT in a subset of T-lineage ALL patients in
CR1; however, this did not consider modern chemotherapy
results with better EFS. There are subsets of T-ALL that seem to
have aworse prognosis with chemotherapy, but it is not yet known
if SCTwould benefit these patients. This area requires further
study.
MLL+ ALL New treatment recommendation based on
new evidence
C 2+ 5, 11 Current data do not support allogeneic SCTwhen MLL+ ALL is the
sole adverse risk factor. The presence of MLL+ along with other
risk factors (age, WBC, prednisone response, other cytogenetic
abnormalities) has been used to define very high risk groups for
which allogeneic SCT may be recommended.
Hypodiploid ALL (<44 chromosomes) New treatment recommendation based on
expert opinion
D 4 Outcomes remain dismal for hypodiploid ALL treated with modern
chemotherapy only. While there are no published data to make
a recommendation, based on expert opinion, allogeneic SCT may
be considered. This area requires further study.
Allogeneic SCT vs chemotherapy for ALL after primary
induction failure §
New evidence changed the original
recommendation
C 2+ 4 Allogeneic SCT is recommended for ALL patients with primary
induction failure who subsequently achieve complete remission.
Allogeneic SCT vs chemotherapy for persistent MRD
positivity (in CR1 or CR2)
New treatment recommendation based on
expert opinion
D 4 Based on expert opinion allogeneic SCT may be considered for
patients who have been identified by a validated assay as very high
risk due to detection of persistent MRD; however, this is an
evolving field in need of further study.
Allogeneic SCT vs Chemotherapy for ALL in Second Morphologic Complete Remission
Early marrow relapse (during or within 6 months of
therapy completion or <36 months from diagnosis)
in precursor-B ALL
New evidence changed the original
recommendation
B 2++ 11 Due to a significant benefit in survival outcomes, allogeneic SCT is
recommended for patients in CR2 who have experienced an early
marrow relapse.
Later marrow relapse in precursor-B ALL New evidence changed the original
recommendation
B 2++ 11 There may be a small EFS advantage for patients with allogeneic SCT,
but taking into account salvage therapy, the outcomes with
chemotherapy and SCT are equivalent for late marrow relapse.
The decision to utilize SCT in these patients should be made by
the patient, family, and transplant team with consideration of the
risks and benefits involved.
T-ALL New treatment recommendation based on
evidence from the original EBR
C 2+ 22 Based on one small study and expert opinion, allogeneic SCT is
recommended for T-lineage ALL in CR2 after a marrow relapse;
however, further study is needed.
(Continued )
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Table 1. (Continued )
Indication for SCT Original vs New Rec
Tx Rec
Grade*
Highest Level
of Evidence† Ref. No.‡ Treatment Recommendation Comments
Isolated CNS relapse New treatment recommendation based on
new evidence
B 2++ 12 Allogeneic SCT is not recommended for isolated CNS relapse in
precursor-B ALL because survival of these patients with chemo/
radiotherapy is equivalent. There are insufficient data to make
a recommendation regarding allogeneic SCT for treatment of an
isolated CNS relapse in T-lineage ALL.
Isolated testicular relapse No recommendation D 4 No data are available to make a recommendation regarding
allogeneic SCT for treatment of an isolated testicular relapse.
Allogeneic SCT vs chemotherapy for ALL in third or greater
morphologic complete remission
New treatment recommendation based on
new evidence
C 2+ 15 Although patients with ALL in third or greater remission have a poor
prognosis regardless of treatment, allogeneic SCT is
recommended because it improves survival outcomes.
Allogeneic SCT vs chemotherapy for ALL not in
morphologic complete remission
New treatment recommendation based on
expert opinion
D 4 There are no data to recommend allogeneic SCT for patients in
active relapse with measurable disease. SCT for patients with ALL
with measurable disease produces long-term disease-free
survivals <10%. The decision to use SCT in these patients should
be made by the patient, family, and transplant team with
consideration of the risks and benefits involved.
TRANSPLANTATION TECHNIQUES
Related vs unrelated donor allogeneic SCT New treatment recommendation based on
new evidence
B 2++ 23-24 Survival outcomes after HLA-matched related or unrelated donor
allogeneic SCTare similar. Based on studies in acute lymphoblastic
and myeloid leukemia, in the absence of an HLA-matched related
donor, an HLA-matched unrelated donor allogeneic SCT (using
marrow, peripheral or cord blood) is an acceptable alternative.
Autologous vs allogeneic SCT New treatment recommendation based on
new evidence
C 2++ 29 There are no data to support a benefit for autologous SCT in
children. It is not a recommended treatment, nor is it standard
practice.
Maternal vs paternal donor allogeneic SCT No recommendation based on new evidence 2+ 30 There are insufficient data to make a treatment recommendation
regarding use of a maternal vs paternal donor for allogeneic SCT.
HLA-matched vs mismatched unrelated donor
allogeneic SCT
New treatment recommendation based on
new evidence
C 22 31 Allogeneic SCTusing the best possible HLA-match is recommended.
Although HLA-mismatched unrelated donor allogeneic SCT may
result in higher morbidity and mortality than HLA-matched
unrelated donor allogeneic SCT, this does not preclude
performing an HLA-mismatched unrelated donor allogeneic SCT.
Imatinib versus no imatinib therapy pre and/or
post-allogeneic SCT for Ph+ ALL
No recommendation based on new evidence 2+ 32 There are insufficient data to make a treatment recommendation
regarding the use of imatinib therapy with allogeneic SCT in
children with Ph+ ALL.
Comparison of conditioning regimens New evidence strengthens the original
recommendation
B 2+ 33-34 Myeloablative TBI-containing regimens have better survival
outcomes than non-TBI-containing regimens.
ALL indicates acute lymphoblastic leukemia; Rec., recommendation Tx, treatment; Ref., reference; SCT, stem cell transplantation; CR1, first complete remission; Ph+, Philadelphia chromosome positive; EBR,
evidence-based review; TKI, tyrosine kinase inhibitor; EFS, event-free survival; MLL, mixed-lineage leukemia; CR2, second complete remission; MRD, matched related donor; CNS, central nervous system; MUD,
matched unrelated donor; TBI, total body irradiation.
*Definitions for Grade of Recommendation: A 5 At least one meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++, and directly applicable to the target population; or a systematic
review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results; B5A body of evidence including studies
rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+; C5 A body of evidence including studies rated as
2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++; D5 Evidence level 3 or 4; or extrapolated evidence from studies
rated as 2+.
†Definitions for Levels of Evidence: 1++ High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias; 1+ Well conducted meta analyses, systematic
reviews of RCTs, or RCTs with a low risk of bias; 1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; 2++ High quality systematic reviews of case-control or cohort studies; or high quality
case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+Well conducted case control or cohort studies with a low risk of confounding,
bias, or chance, and a moderate probability that the relationship is causal; 2- Case control or cohort studies with a high risk of confounding, bias, or chance, and a significant risk that the relationship is not causal; 3 Non-
analytic studies (eg, case reports, case series); 4 Expert opinion.
‡The references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence described in each section of the review.
§Primary induction failure defined as patients who failed to achieve first remission after the first 4-6 weeks of initial induction therapy, but who subsequently achieve a complete remission.
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Biol Blood Marrow Transplant 18:505-522, 2012 509Pediatric ALL EBR Update 2012Ph1 ALL receiving allogeneic or autologous BMT
versus chemotherapy without TKI therapy. Wheeler
et al. [9] found no significant difference in 10-year
EFS or 10-year OS, and Uderzo et al. [10] found no
significant difference in 4-year DFS between very
high-risk pediatric patients with ALL who underwent
allogeneic SCT vs chemotherapy. Pui et al. [11] re-
ported a significantly worse DFS and OS in pediatric
patients with ALLwith t(4;11) treated with autologous
or allogeneic BMT versus chemotherapy.Transplantation versus Chemotherapy for
Pediatric ALL in $ CR2
Table 3 presents a summary of the 7 new studies
and 5 original ALL EBR studies comparing transplan-
tation vs chemotherapy for patients with ALL in $
morphologic CR2 or relapsed disease. The quality
ratings of these studies range from 211 to 21.
A retrospective, multicenter study by Eapen et al.
[12] compared the outcomes in patients with precursor
B-ALL in CR2 from 3 Pediatric Oncology Group
(POG9110, 9310, and 9411) chemotherapy trials to pa-
tients reported to theCenter for InternationalBloodand
Marrow Transplant Research (CIBMTR) registry who
underwent HLA-matched sibling allogeneic SCT. A
significant benefit in leukemia-free survival (LFS) and
OSwas reported specifically for patients in early relapse
who underwent an HLA-matched allogeneic SCT with
a total body irradiation (TBI)-containing conditioning
regimen versus those who received chemotherapy only.
Another retrospective, multicenter study by Eapen
et al. [13] reported no significant difference in LFS or
OS between pediatric patients with ALL in CR2 after
central nervous system (CNS) relapse who underwent
an HLA-matched sibling allogeneic SCT versus those
who received chemo/radiotherapy only.
Malempati et al. [14] reported no significant differ-
ence in 2-year EFS between pediatric patients with
ALL in CR2 in the COG CCG-1952 trial whose sal-
vage therapy was any SCT (MRD,MUD, or unrelated
cord blood allogeneic SCT, or autologous SCT)
versus chemotherapy only in a comparison that
combined all types of relapse risk (early, late, isolated
extramedullary relapse).
Tallen et al. [15] found no significant difference
in 10-year EFS between pediatric patients with ALL
in CR2 who underwent any SCT (MRD, MUD,
MMRD, mismatched unrelated donor [MMUD], or
autologous SCT) vs those who received chemotherapy
alone. However, there was a significant improvement
in 10-year EFS for those patients who underwent an
MRD or MUD allogeneic SCT vs those who under-
went an MMRD or MMUD allogeneic SCT or autol-
ogous SCT.
Saarinen-Pihkala et al. [16] reported a significant
improvement in 10-year EFS for pediatric patientswith ALL in $CR3 who underwent an HLA-MRD
or MUD allogeneic SCT vs those who received
chemotherapy alone in Nordic Society for Pediatric
Hematology and Oncology (NOPHO) trials.
Einsiedel et al. [17] reported a significant improve-
ment in 15-year EFS in pediatric patients with ALL
who experienced abonemarrow relapse after treatment
in the ALL-REZ BFM 87 trial and who subsequently
underwent an MRD allogeneic SCT vs chemother-
apy/radiotherapy in CR2.
Gaynon et al. [18] reportedno significant difference
in 5-year DFS among pediatric patients with ALL in
CR2 in the COG CCG-1941 trial who underwent an
MRD allogeneic BMT or were randomized to receive
either an alternative (MUD allogeneic or autologous)
BMT or chemotherapy.
Table 3 also presents 4 high-quality (211) studies
used to make a treatment recommendation in the 2005
pediatric ALL EBR on the use of transplantation vs
chemotherapy to treat pediatric patients with ALL in
CR2. Barrett et al. [19],Wheeler et al. [20], andUderzo
et al. [21] reported a significant improvement in 5-year
LFS, 4-year EFS, or 5-year DFS, respectively, for pa-
tients who underwent allogeneic BMT versus chemo-
therapy only, whereas Harrison et al. [22] found no
significant difference in8-yearEFS. In addition, a study
by Borgmann et al. [23], which was not used to make
a treatment recommendation in the original EBR, is
provided in this update as level 21 evidence for a treat-
ment recommendation specifically regarding alloge-
neic SCT versus chemotherapy for T-lineage ALL in
CR2. The study reported significantly better 5-year
EFS for patients with T-lineage or high-risk precur-
sor-B ALL who underwent an MUD allogeneic BMT
compared to those who received chemotherapy only.RELATEDVERSUS UNRELATED DONOR
ALLOGENEIC SCT FOR PEDIATRIC ALL
Insufficient data resulted in no recommendation
regarding the efficacy of related versus unrelated do-
nor allogeneic SCT in the original pediatric ALL
EBR. Published since the original pediatric ALL
EBR, and briefly summarized below, are 5 studies
comparing related versus unrelated donor allogeneic
SCT as treatment for pediatric patients with ALL in
morphologic CR1 (n 5 1 study) or with a majority of
patients in $ morphologic CR2 or with relapsed dis-
ease (n 5 4 studies). Table 4 presents a detailed sum-
mary of the study designs, patient populations, and
outcomes from this new evidence, ranging in quality
from 211 to 21.
In a single-center retrospective study, Tomblyn
et al. [24] reported inferior 5-year DFS and OS for pe-
diatric patients (62% were \18 years) with ALL in
CR1 or CR2 who underwent MMUD allogeneic
SCT compared to all other donor sources (MRD,
Table 2. Transplantation versus Chemotherapy for Pediatric ALL in Morphologic CR1
Reference & Patient
Populations
Quality/
Strength of
Evidence* Treatment Regimen
Sample
Size
Age, Yrs,
Median
(Range)
% WBC
>100,000
%
Ph+
% T
Lineage
Follow-up
(in Months)
Median (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS/LFS†
% OS
(95% CI)
Signif.
OS†
Update data published since January, 2005
[2] Ribera 2007 1+ Total 76 NR (<1-17) 78 (15.6-149) ITT 5-yr DFS P 5.36 5-year OS P 5 .23
1993-2002 Autologous SCT 38 53% 7% 47% 5% 44% (29-60%) 45% (31-62%)
Prospective, Multicenter Chemotherapy 38 39% 14% 37% 0% 46% (32-62%) 57% (43-73%)
PETHEMA ALL-93
Very HR ALL in CR1 2+ Total 100
Donor (Allo SCT) 24 46% 7% 58% NR 45% (37-55%) P 5 .96 48% (30-67%) P 5 .83
No donor (auto or chemo) 76 45% (27-65%) 51% (43-61%)
[3] Arico 2010 2++ Total 542 7.8 (.7-18) NR 100% NR 75.6 (1.2-138) 3% 5-year DFS P < .001 5-year OS P 5 .003
1995-2005 Any SCT (MRD, MUD,
or MMRD allo, or auto)
325 43.5% ± 2.9% Any SCT vs Chemo 54% ± 2.8% Any SCT
vs ChemoRetrospective, Multicenter
Ph+ ALL in CR1 Chemotherapy 217 34.2% ± 3.7% 48.3% ± 3.5%
No TKI therapy
[4] Balduzzi 2008 2+ Total 357 NR 60 (NR) NR 5-yr DFS P 5 .02 5-year OS P 5 .12
1995-2000 Donor (MSD allo) 77 7 (4-12) 9% 39% 56.7% ± 5.7% Donor vs No donor 50.1% ± 3.1%
Prospective, Multicenter No donor 280 7 (3-11) 24% 45% 40.6% ± 3.1% 56.4% ± 5.9%
Collaborative (5 groups) (ITT)
Very HR‡ ALL in CR1
Donor 25 56% ± 9.9% P 5 .03 NR NR
No donor (Induction failures only) 58 26.5% ± 5.9% Donor vs No donor
MRD Allo SCT 55 63.1% ± 6.6% P 5 .017 NR NR
MUD Allo SCT 43 41.6% ± 7.6% MRD vs MUD
or ChemoChemotherapy
(By actual treatment)
259 42.5% ± 3.2%
[5] Mann 2010 2+ Total 277 NR (#1) 63% NR 1% 60 (0-108) NR 5-year DFS P 5.09 5-year OS P 5.32
1999-2006 Allo SCT (MSD, MUD
or MMUD)
Medium risk§ Medium risk§
Retrospective, Collaborative 37 60.9% ± 11.4% 65.2% ± 10.6%
Interfant-99 trial Chemotherapy 240 53.8% ± 4.4% 60.8% ± 4.1%
MLL+ ALL in CR1
High risk P 5 .01 High risk P 5 .001
Allo SCT 59% ± 12.8% 66% ± 12.4%
Chemotherapy 22.2% ± 7.8% 19.3% ± 6.1%
[6] Schrauder 2006 2+ Total 179 <18 (NR) NR 100% 78 (NR) ITT 5-yr DFS P 5 .01 5-year OS P 5 .01
1990-2000 Allo BMT 36 67% ± 8% Allo BMT vs Chemo 67% ± 8% Allo BMT
vs ChemoRetrospective, Multicenter Chemotherapy 143 62.5% 5% 42% ± 5% 47% ± 5%
ALL-BFM-90 and 95 MSD Allo 23 60.9% 0% 65% ± 10% P 5 NS
Very HRk TALL CR1 MUD or MMRD Allo 13 53.8% 31% 69% ± 13%
[7] Schultz 2009 2+ Total 57 NR (1-21) NR 100% NR NR NR 3-year EFS P 5.14 NR NR
2002-2006 MSD Allo BMT 21 56.6% ± 21.5%
Prospective, Multicenter Alternative donor BMT 11 71.6% ± 19%
COG AALL0031
Very HR Ph+ ALL
Chemo + imatinib
maintenance
25 87.7% ± 10.9%
TKI – with chemo only
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Original Pediatric ALL EBR data
[9] Wheeler 2000 2++ Total 452 96 Overall 10-yr EFS P 5 NS 10-yr OS P 5 NS
1985-1997 Multicenter Allo BMT (MRD/ MUD) 101 NR 73% 14% 41% 60 (NR) 17.8% 50.4% 61.2%
Retrospective analysis Chemotherapy 351 NR 73% 3% 36% NR 3.1% 39.7% 54%
MRC UKALL X & XI
ALL in CR1
[8] Arico 2000 2++ Total 267 100% 87.6 Overall 5-yr DFS P < .001 5-yr OS P 5 .002
1986-1996 Any BMT 120 6.9 (.4-20) 30% 2% 65% ± 8% Any BMT 72% ± 8% Any BMT
vs ChemoRetrospective, multicenter Chemotherapy 147 7.5 (.4-20) 50% 3% 5% 25% ± 4% vs Chemo 42% ± 4%
Ph+ ALL in CR1
Allo BMT 95
MRD 38 8%
MUD 21 43%
MMRD 16 44%
Other undefined Allo 20 25%
Autologous BMT 25 12%
[11] Pui 2002 2++ Total 230 0.65 NR 0% <1% 84 Overall Hazard DFS P 5 .014 Hazard OS P 5 .004
1983-1995 Any BMT 56 (0.01-20.9) (18-200) 20% 1.61 (1.1-2.34) 1.76 (1.08-2.45)
Retrospective,
multicenter 11 coop
groups or single
centers, US+ Europe
Chemotherapy 174 At Dx 4% 1.0 1.0
MRD 15 20% 1.3 (0.67-2.52) P 5 .44 1.48 (0.47-2.48) P 5 .26
MUD 14 21% 1.47 (0.74-2.93) P 5 .27 1.9 (0.11-3.92) P 5 .078
ALL with t(4;11) Other allo 17 29% 2.22 (1.27-3.91) P 5 .0055 2.54 (1.15-3.92) P 5 .0008
In CR1 Autologous BMT 9 0% 1.29 (0.51-3.25) P 5 .59 0.83 (0-1.67) P 5 .71
[10] Uderzo 1997 2++ Total 160 48 Overall 4-yr DFS P 5 NS NR NR
1986-1994 Allo BMT 30 8.3 (.1-15) 60% 20% 60% 10% 58.5% ± 9.3%
Prospective, multicenter Chemotherapy 130 5.7 (.7-15) 69% 1% 48% 4% 47.7% ± 4.8%
AIEOP & GITMO
HR** ALL in CR1
ALL indicates acute lymphoblastic leukemia; CR1, first complete remission; Ph+, Philadelphia chromosome positive; TRM, treatment-related mortality; EFS, event-free survival; DFS, disease-free survival; LFS,
leukemia-free survival; CI, confidence interval; Signif., significance; OS, overall survival; PETHEMA, Programa para el Estudio de la Terapeutica en Hemopatıa Maligna; HR, high risk; Allo, allogeneic; SCT, stem cell
transplantation; NR, not reported; Auto, autologous; MRD, matched related donor; MUD, matched unrelated donor; MMRD, mismatched related donor; TKI, tyrosine kinase inhibitor; MSD, matched sibling donor;
ITT, intention-to-treat analysis; MLL, mixed-lineage leukemia; BMT, bone marrow transplantation; COG, Children’s Oncology Group; EBR, evidence-based review; Dx, diagnosis; AIEOP, Associazione Italiana di Ema-
tologia ed Oncologia Pediatricia; GITMO, Gruppo Italiano Trapianto di Midollo Osseo; WBC, white blood cell count; MRC, Medical Research Council; BFM, Berlin-Frankfurt-Munster.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†NS: Not significant P > .05.
‡Very high risk 5 at least one of the following: induction failure; Ph+ or t(4;11); poor response to prednisone.
§High risk 5 MLL+, age <6 months, and either WBC $300 g/L or poor prednisolone response; Low risk 5 no MLL rearrangement; Medium risk 5 all others.
kVery high risk5 Poor prednisone response; nonresponse on day 33; Ph+ or t(4;11); BCR/ABL orMLL/AF4 rearrangement, plus one of the following: T-ALL, pro-B-cell ALL, coexpression of myeloid markers, or BRM-
RF of 1.7 or higher.
**HR 5 Ph+ t(4;11), BFM risk index >1.7, T-immunophenotype with WBC >100 x 109/L or with day 7 steroid resistance, and failure to obtain CR at day 42 of induction therapy.
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Table 3. Transplantation vs Chemotherapy for Pediatric ALL in $ Morphologic CR2
Reference & Patient
Populations
Quality/
Strength
of Evidence* Treatment Regimen
Sample
Size
Age, Yrs,
Median
(range)
% WBC
>100,000
%
Ph+
% T
Lineage
Follow-up
(in months)
Median (range) % TRM
% EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS/LFS†
% OS
(95% CI)
Signif.
OS†
Update data published since January, 2005
[12] Eapen 2006 2++ Total 374 NR ITT 8-yr LFS P < .001 8-yr OS P < .003
1991-1997 MSD Allo BMT 186 8 (1-18) 9% 0% 101 (16-160) 13% In early relapse:
TBI + Allo
vs Chemo
In early relapse:
TBI + Allo
vs Chemo
Retrospective, Multicenter Early relapse‡; no TBI 19 8% (1-24%) 18% (5-37%)
POG 9110, 9310, & Early relapse; TBI 92 41% (31-52%) 44% (33-55%)
9411 chemo trials
vs CIBMTR
Late relapse; no TBI 14 30% (10-54%) 32% (23-40%)
Late relapse; TBI 61 60% (46-71%) 63% (49-74%)
Pre-B ALL in CR2 Chemotherapy 188 5 (1-18) 8% 0% 103 (34-159) 10%
Early relapse 110 23% (15-31%) 32% (23-40%)
Late relapse 78 59% (47-69%) 66% (54-76%)
[13] Eapen 2008 2++ Total 209 NR (<18) NR 8-yr ITT 8-yr LFS P 5 .80 8-yr OS P 5 .14
1990-2000 MSD Allo SCT 60 22% 23% 108 (NR) 22% 58% 62%
Retrospective, Multicenter Chemo/radiotherapy 149 13% 7% 96 (NR) 9% 66% 67%
POG 9061 & 9412
Chemo trials vs CIBMTR
ALL in CR2 after isolated
CNS relapse
[15] Tallen 2010 2+ Total 440 NR (<19) NR NR NR 120 (NR) NR 10-yr EFS P 5 .59 NR NR
1990-1995 Any SCT 117 37% ± 5%
Prospective, Multicenter Chemotherapy 323 35% ± 3%
ALL-REZ BFM 90
ALL in CR2 MRD Allo SCT 61 43% ± 6% P 5 .02
MUD Allo SCT 19 42% ± 11% MRD/MUD
MMRD/URD Allo SCT 7 14% ± 13% vs
Autologous SCT 30 27% ± 8% MMRD/URD
[16] Saarinen-Pihkala 2006 2+ Total 202 NR NR NR 10-yr EFS P < .01 NR NR
1981-2001 MRD or MUD Allo SCT 62 5.5 (1-14) 6% 19% 37%
Retrospective, Multicenter Chemotherapy 140 4.8 (1-14) 6% 8% 15%
NOPHO trials
[17] Einsiedel 2005 2+ Total 172 NR (#18) NR NR NR 188 (NR) 15-yr EFS P 5 .026 NR NR
1987-1990 MRD Allo SCT 27 15% 59% ± 7%
Prospective, Multicenter Chemo/radiotherapy 145 4% 30% ± 4%
ALL-REZ BFM 87
ALL in CR2
[18] Gaynon 2006 2+ Total 122 NR NR NR NR ITT 5-yr DFS P 5 NS NR NR
1995-1998 MRD Allo BMT 50 4.7 (.6-17) 4% 29% ± 7% (for all comparisons)
Prospective, Multicenter Alternative BMT§ 37 6.2 (.7-17) 19% 21% ± 7%
COG CCG-1941 Chemotherapy§ 35 3.1 (.4-18) 9% 20% ± 7%
ALL in CR2
[14] Malempati 2007 22 Total 158 (Mean) NR NR NR 28.8 (NR) NR 2-yr EFS P 5 .39 NR NR
1996-2000 Any SCT (Allo or Auto) 77 4.7 (1-9) 49.5% ± 6.1%
Retrospective, Multicenter Chemotherapy 81 4.7 (1-9) 49.1% ± 6.4%
COG CCG-1952 trial (By actual salvage Tx)
SR ALL in CR2
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Original Pediatric ALL EBR data
[19] Barrett 1994 2++ Total 510 NR NR yr LFS P < .001 NR NR
1983-1991 MSD Allo BMT 255 7 (.5-18.4) 7% 8% 27% 4 ± 3% Allo BMT vs Chemo
Matched-pair, Multicenter Chemotherapy 255 6 (.4-18.1) 7% 8% 14% 1 ± 3%
POG 8303, 8304, 8710,&
8862 vs CIBMTR
ALL in CR2
[20] Wheeler 1998 2++ Total 432 NR (1-14) NR NR 24 Minimum yr EFS P 5 .05 NR NR
1985-1990 Allo BMT 110 17% 2.6% Allo BMT vs Chemo
Retrospective, Multicenter Autologous BMT 61 7% 5% 5.4%
MRC UKALL X Chemotherapy 261 10% 5% 8.2%
ALL in CR2
MRD Allo BMT 83 6%
MUD Allo BMT 27 5%
[21] Uderzo 1995 2++ Total 287 NR (0-18) NR NR 74 Overall r DFS P 5 .006 NR NR
1980-1989 MRD Allo BMT 57 14% 19.3% 1.1% Allo BMT vs Chemo
Retrospective, Multicenter Chemotherapy 230 14% 2.6% 1.7%
AIEOP & GITMO
ALL in CR2
[22] Harrison 2000 2++ Total 206 NR (0-14) NR NR 72 (48-108) NR yr EFS P 5 .60 NR NR
1991-1995 Donor (MRD or MUD) 67 36% 45%
Retrospective, Multicenter No donor (Chemo or Auto) 139 55% 37%
MRC UKALL R1
ALL in CR2
[23] Borgmann 2003 2+ Total 162 NR (#18) NR NR yr EFS P < .001 NR NR
1983-1994 MUD BMT 81 11% 49 (NR) 30% 42%
Retrospective, Multicenter Chemotherapy 81 11% 95 (NR) 4% 17%
Matched-pair analysis
ALL-REZ BFM
ALL in CR2
ALL indicates acute lymphoblastic leukemia; CR, complete remission; Ph+, Philadelphia chromosome positive; TRM, treatment-related mortality; EFS vent-free survival; DFS, disease-free survival; LFS, leukemia-free
survival; CI, confidence interval; NR, not reported; OS, overall survival; MSD, matched sibling donor; Allo, allogeneic; BMT, bone marrow transplanta n; TBI, total body irradiation; POG, Pediatric Oncology Group;
CIBMTR, Center for International Blood and Marrow Transplant Research; CNS, central nervous system; EFS, event-free survival; SCT, stem cell tra plantation; ALL-REZ BFM, Relapsed Acute Lymphoblastic Leu-
kemia Berlin-Frankfurt-Munster Study Group; MRD, matched related donor; MUD, matched unrelated donor; MMRD, mismatched related donor RD, unrelated donor; NOPHO, Nordic Society for Pediatric
Hematology and Oncology; NS, not significant; COG, Children’s Oncology Group; Auto, autologous; Tx, treatment; EBR, evidence-based review; AIE P, Associazione Italiana di Ematologia ed Oncologia Pediatricia;
GITMO, Gruppo Italiano Trapianto di Midollo Osseo; MRC, Medical Research Council; SR, standard risk.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
‡Early relapse <36 months; late relapse $36 months.
§Randomized to alt. BMTor chemo; 41 of 113 refused randomization.
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or cord blood), but the differences were not significant.
Smith et al. [25] reported the results of a single-
center study of pediatric patients with ALL in CR2,
which compared outcomes after HLA-matched
sibling donor allogeneic BMT, HLA-well/PMUD or
MMUD allogeneic BMT, and unrelated umbilical
cord blood. Five-year LFS was significantly lower in
recipients of MMUD allogeneic BMT, but compara-
ble in all other groups.
Kennedy-Nasser et al. [26] reported no significant
difference in 3-year DFS in pediatric patients with
ALL in CR1 (23%) or CR2 (77%) who underwent
allogeneic SCT from an HLA-matched sibling donor
versus an MUD or MMUD.
Mu~noz et al. [27] reported comparable 5-year EFS
in pediatric patients with ALL in CR2, from the Span-
ish SHOP-94 and 99 and PETHEMA trials, who un-
derwent an HLA-identical sibling or syngeneic donor
allogeneic SCT versus an unrelated donor allogeneic
SCT.
Sanders et al. [28] reported a significantly lower
DFS and OS among infants (diagnosed at age \1
year) with ALL in CR1, CR2/3, or relapse who under-
went a nonsibling related donor allogeneic SCT vs an
HLA-matched sibling donor allogeneic SCT at a sin-
gle center. DFS and OS were also lower in infants who
received an unrelated donor allogeneic SCT compared
to those who underwent an HLA-matched sibling
donor allogeneic SCT, but the difference was not
statistically significant.
Roy et al. [29] reported no significant difference
in 3-year EFS or OS between pediatric patients with
ALL in CR1 who underwent an MRD versus MUD
allogeneic BMT.OTHER COMPARATIVE STUDIES OF
ALLOGENEIC SCT FOR PEDIATRIC ALL
Published since the original pediatric ALL
EBR, and briefly summarized below, were 7 comp-
arative studies that investigated the impact of
transplantation-related factors, suchas allogeneic versus
autologous SCT (n 5 1 study), donor source (n 5 1
study), donor match (n 5 2 studies), pre- and/or post-
allogeneic SCT imatinib therapy (n5 1 study), and con-
ditioning regimen (n5 2 studies) on survival outcomes
in pediatric patients with ALL. Table 5 presents a de-
tailed summary of the study designs, patient popula-
tions, and outcomes from this new evidence. The
quality ratings of the 5 studies ranged from 211 to 22.
Allogeneic versus Autologous SCT for Pediatric
Patients with ALL
There was one study published since the original
pediatric ALL EBR, which specifically compared the
use of allogeneic versus autologous SCT for pediatricpatients with ALL. A retrospective analysis by Badell
et al. [30] found no significant difference in 14-year
EFS in pediatric patients with ALL inCR2who under-
went an allogeneic or autologous SCT depending on
the availability of an HLA-matched sibling donor.
The quality ratings for the 8 studies comparing au-
tologous versus allogeneic SCT in the original pediatric
ALL EBR ranged from 21 to 22, and no recommen-
dation was made based on a lack of evidence. There-
fore, the original EBR studies of autologous versus
allogeneic SCT are not presented in detail in this
update.
Maternal versus Paternal Donor in T Cell-
Depleted Allogeneic SCT
In a retrospective analysis, Stern et al. [31] reported
better 5-year EFS in pediatric/young adult patients
with ALL from 2 centers who underwent a T cell-
depleted, haploidentical allogeneic SCT from the
mother versus the father, but the difference was not
statistically significant. There were no data in the orig-
inal EBR on this topic.
Bone Marrow versus Cord Blood Unrelated
Donor Transplantation
There was one study published since the original
pediatric ALL EBR, which compared the impact of
bone marrow versus cord blood unrelated donor
transplantation for pediatric ALL. A retrospective
CIBMTR and National Cord Blood Program registry
study by Eapen et al. [32] reported similar outcomes in
5-year LFS among pediatric patients with ALL (63%)
or acute myelogenous leukemia (AML) who under-
went an MUD or MMUD allogeneic BMT versus an
HLA-matched or 1 or 2-antigen mismatched unre-
lated cord blood transplant.
Matched versus Mismatched Unrelated Donor
Transplantation
There was one study published since the original
pediatric ALL EBR, which compared the impact of
MUD versus MMUD allogeneic SCT for pediatric
ALL. A retrospective analysis by Afify et al. [33] re-
ported no significant difference in 3-year EFS between
pediatric patients with ALL in CR3 who underwent an
MUD versus MMUD allogeneic SCT at a single
center in the United Kingdom. There were no data
in the original EBR on this topic.
Imatinib versus No Imatinib Therapy Pre-
and/or Post-Allogeneic SCT
Burke et al. [34] reported a single-center study
showing no significant difference in the 3-year DFS
or OS between pediatric patients with Ph1 ALL in
CR1 or CR2 who received imatinib pre and/or post-
myeloablative allogeneic SCT versus those who did
Table 4. Related Versus Unrelated Donor Allogeneic SCT for Pediatric ALL
Reference and
Patient Populations
Quality/Strength
of Evidence* Treatment Regimen
Sample
Size
Age, Yrs
Median
(range)
Median
Duration
CR1 (mo) % Ph+
% T
Lineage
Follow Up
(in months)
Median (range) % TRM
% EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS/LFS†
% OS
(95% CI)
Signif.
OS†
Update data published since January 2005
[24] Tomblyn 2009 2++ Total 242 13 (.5-55) NR 18% 10% 69.6 (12-174) 2-yr 5-yr LFS P 5 .09 5-yr OS P 5 .12
1990-2005 MRD Allo SCT 113 26% 40% (31-49%) 42% (33-51%)
Retrospective, Single Center MUD Allo SCT 12 33% 42% (14-70%) 42% (14-70%)
ALL in CR1 or CR2 PMUD Allo SCT 21 38% NR 38% (18-58%)
(58% CR2) MMUD Allo SCT 45 62% 27% (14-40%) 31% (17-45%)
62% <18 yrs Cord Blood Allo SCT 51 24% 49 (34-64%) 51% (46-66%)
[25] Smith 2009 2++ Total 87 (<18) NR 1-yr 5-yr LFS P 5 .05 NR NR
1990-2007 MSD Allo SCT 32 4.6 (NR) 25.2 13% 79 (34-132) 9% 41% (24-68%) All others
vs MMUDProspective, Single Center MUD/PMUD Allo SCT 18 3.4 (NR) 24 0% 112 (41-174) 22% 57% (35-80%)
ALL in CR2 MMUD Allo SCT 16 5.4 (NR) 13.2 19% 94 (84-162) 69% 19% (5-40%)
Cord Blood Allo SCT 21 4.2 (NR) 26.4 10% 49 (12-94) 24% 43% (23-63%)
[26] Kennedy-Nasser 2008 2+ Total 83 NR NR 3-yr DFS P 5 .84 NR NR
1998-2007 MSD Allo SCT 41 9.1 (2-20) 17% 78 (11-127) 4.9% 72% (55-84%)
Retrospective, Single Center Alternative Allo SCT 42 7.8 (.8-19) 12% 34 (11-79) 19.5% 62% (45-75%)
ALL in CR1 or CR2 (MUD or MMUD)
(77% CR2)
[27] Mu~noz 2008 2+ Total 58 NR 0% NR 5-yr EFS P 5 .25 NR NR
1999-2004 Related donor Allo SCT 31 8 (1-17) 54 (24-80) 16% 43% ± 9%
Prospective, Multicenter URD Allo SCT 27 9 (3-14) 52 (22-85) 37% 36% ± 9%
GETMON
ALL in CR2
[28] Sanders 2005 2+ Total 40 .55 (0-.98) NR NR NR 84 (12-204) 18% DFS P 5 .03 OS P 5 .02
1982-2003 MSD Allo SCT 8 Estimates not
reported
MSD vs MMRD Estimates not
reported
MSD vs MMRD
Retrospective, Single Center MMRD Allo SCT 16
ALL in CR1 (43%) or URD Allo SCT 16 P 5 .06 P 5 .49
CR2/3 or relapse (58%) MSD vs URD MSD vs URD
[29] Roy 2005 2+ Total 27 NR 100% 0% 42 (21-84) 19% 3-yr EFS P 5 .10 3-yr OS P 5 .10
1997-2002 MRD Allo BMT 11 5.1 (1-18) 45% (17-71%) 45% (17-71%)
Prospective, Multicenter MUD Allo BMT 16 5.2 (1-18) 68% (39-85%) 74% (45-89%)
MRC ALL-97 (By actual treatment)
Ph+ ALL in CR1
SCT indicates stem cell transplantation; ALL, acute lymphoblastic leukemia; CR, complete remission; Ph+, Philadelphia chromosome positive; TRM, treatment-related mortality; EFS, event-free survival; DFS, disease-
free survival; LFS, leukemia-free survival; CI, confidence interval; Signif., significance; OS, overall survival; PMUD, partially mismatched unrelated donor; NR, not reported; MMUD, mismatched unrelated donor; MSD,
matched sibling donor; Allo, allogeneic; MUD, matched unrelated donor; GETMON, Spanish Working Party for BMT in Children; URD, unrelated donor; MMRD, mismatched related donor; MRD, matched related
donor; BMT, bone marrow transplantation; MRC, Medical Research Council.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
8
:5
0
5
-5
2
2
,
2
0
1
2
5
1
5
P
e
d
ia
tric
A
L
L
E
B
R
U
p
d
a
te
2
0
1
2
Table 5. Other Comparative Studies of Allogeneic SCT for Pediatric ALL
Reference &
Patient Populations
Quality/Strength
of Evidence* Treatment Regimen
Sample
Size
Age, Yrs
Median
(range)
Median
Duration
CR1 (mo) % Ph+
% T
Lineage
Follow Up
(in months)
Median (range)
%
TRM
% EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS/LFS†
% OS
(95% CI)
Signif.
OS†
Update data published since January 2005
Autologous vs Allogeneic SCT for Pediatric ALL
[30] Badell 2005 2++ Total 219 8.7 (1-16) NR NR 75 (NR) 14-yr EFS P 5.43 NR NR
1983-1998 Donor (Allo SCT) 90 12% 24% 39% ± 5%
Retrospective, Multicenter No Donor (Auto SCT) 129 17% 7% 32% ± 4%
GETMON
ALL in CR2
Maternal vs Paternal Donor in T–Cell-Depleted Haploidentical Allogeneic SCT
[31] Stern 2008 2+ Total ALL 67 Overall at SCT NR NR NR 40.8 (6-166) 5-yr EFS P 5 .10 NR NR
1993-2006 Maternal Donor Allo SCT 24 19 (2-52) Overall 45.8% ± 10%
Retrospective, 2 Centers Paternal Donor Allo SCT 43 17 (2-41) 13.1% ± 6%
Total n5118 (ALL/AML) (ALL)
57% ALL
Overall, 57% in CR
Bone Marrow vs Cord Blood Unrelated Donor Transplantation
[32] Eapen 2007 2+ Total 785 NR (<1-15) NR NR NR NR 5-yr LFS P NR NR
1995-2003 MUD Allo BMT 116 60 (8-123) 36% Not
Retrospective, Registry MMUD Allo BMT 166 59 (11-121) 37% provided;
CIBMTR, NCBP MUD Allo CBT 35 45 (3-124) 60% results
Total n 5 785 (ALL/AML) 1-antigen MMUD CBT LD 44 56 (12-120) 36% reported
63% ALL – Outcomes 1-antigen MMUD CBT HD 157 40 (3-121) 45% as ‘‘similar’’ and
‘‘possibly higher
for MUD CBT’’
not stratified by disease 2-antigen MMUD CBT 267 44 (3-119) 33%
CR1, $ CR2, or relapse
HLA-Matched vs Mismatch Unrelated Donor Transplantation
[33] Afify 2005 22 Total 35 NR (<18) NR NR 3% 45.6 (3-112) 23% 3-yr EFS P 5 .54 NR NR
35% ± 8%
1990-2002 MUD Allo BMT 23 (Comparison
data NR)Retrospective, Single enter MMUD Allo BMT 12
ALL in CR3
Imatinib vs No Imatinib Therapy Pre and/or Post-Allogeneic SCT
[34] Burke 2009 2+ Total 37 Mean NR 100% NR 23 (1.3-153) 3-yr DFS P 5 .99 3-yr OS P 5 .80
1990-2006 Imatinib Group 13 8.3 (2-16) 23% 62% 59%
Retrospective, Single Center No Imatinib Group 24 6.6 (1-14) 21% 53% 58%
Ph+ ALL in CR1 or CR2
Comparison of Conditioning Regimens for Allogeneic SCT
Update data published since January 2005
[35] Marks 2006 2+ Total 502 >24 mos NR CR1 5-yr LFS CR1 P 5 NS 5-yr OS CR1 P 5 NS
1989-1998 Cy + TBI <13 Gy 217 18 (1-56) 55% 19% 67 (8-156) 13% 54% (45-63%) 54% (46-64%)
Retrospective, Multicenter Cy + TBI $13 Gy 81 16 (2-46) 68% 20% 59 (17-149) 19% 51% (35-68%) 60% (44-75%)
CIBMTR and COH Cancer
Center
VP16 + TBI <13 Gy 53 12 (2-41) 46% 19% 52 (7-144) 27% 57% (36-77%) 61% (41-80%)
VP16 + TBI $13 Gy 151 25 (4-54) 56% 20% 65 (3-156) 12% 61% (51-70%) 62% (52-71%)
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ALL in CR1 or CR2
CR2 5-yr LFS CR2 P 5 .007 5-yr OS CR2 P 5 .02
Cy + TBI <13 Gy 20% 33% (24-43%) VP16 + TBI vs 40% (30-51%) VP16 + TBI vs
Cy + TBI $13 Gy 20% 62% (46-76%) Cy + <13 Gy 72% (58-84%)
VP16 + TBI <13 Gy 10% 54% (35-73%) P 5 .001 56% (36-75%) Cy + <13 Gy
VP16 + TBI $13 Gy 12% 50% (35-65%) Cy + $13 Gy vs 50% (35-65%) P 5 .001
Cy + $13 Gy vs
Cy + <13 Gy
Cy + <13 Gy
[36] Gassas 2006 2+ Total 107 NR NR NR 3-yr EFS P 5 NS 3-yr OS P 5 NS
1990-2003 Cy + fTBI (1200 cGy) 45 8.7 (1-18) 16% 16% 51% ± 8% 53% ± 8%
Retrospective, Single Center VP16 + fTBI (1200 cGy) 62 9.4 (.8-18) 15% 21% 47% ± 7% 55% ± 7%
ALL any disease status
Original Pediatric ALL EBR data
[37] Bunin 2003 1+ Total 43 8.7 (.7-20) NR 16% 9% 43.3 (13-64) 3-yr EFS P 5 .03 3-yr OS P 5 .09
1997-2000 Cy + VP16 + TBI 22 9% 58% 67%
Prospective, Multicenter Cy + VP16 + Oral Bu 21 29% 29% 47%
PBMTC, Randomized
ALL any disease status
[38] Davies 2000 2++ Total 627 37 (NR) 3-yr LFS P 5 .005 3-yr OS P 5 .003
1988-1995 Cy + TBI 451 12.9 (.7-20) 19 4% 21% 15% 50% (45-55%) 55% (50-60%)
Retrospective, Multicenter Cy + Bu 176 11.3 (.7-20) 23 3% 13% 23% 35% (28-43%) 40% (32-48%)
IBMTR
ALL any disease status
[39] Weisdorf 1994 2++ Total 123 14 (1-61) NR NR NR 93.6 (NR) 5-yr DFS P 5 NS Overall
OS 34%
NR
1979-1991 Cy + TBI 80 17% 29%
Retrospective, Single Center Cy + fTBI 28 17% 32%
Majority in CR2 (87) Cytarabine + TBI 15 63% 27%
75% <20 yrs
SCT indicates stem cell transplantation; ALL, acute lymphoblastic leukemia; CR, complete remission; Ph+, Philadelphia chromosome positive; TRM, treatment-related mortality; EFS, event-free survival; DFS, disease-
free survival; LFS, leukemia-free survival; CI, confidence interval; Signif., significance; OS, overall survival; NR, not reported; Allo, allogeneic; Auto, autologous; GETMON, SpanishWorking Party for BMT in Children;
AML, acute myeloid leukemia; MUD, matched unrelated donor; BMT, bone marrow transplantation; MMUD, mismatched unrelated donor; CIBMTR, Center for International Blood and Marrow Transplant Research;
NCBP, National Cord Blood Program; CBT, cord blood transplantation; LD, low cell dose; HD, high cell dose; Cy, cyclophosphamide; TBI, total body irradiation; COH, City of Hope; EBR, evidence-based review; Bu,
busulfan; PBMTC, Pediatric Blood and Marrow Transplant Consortium; IBMTR, International Bone Marrow Transplant Research; NS, not significant; fTBI, fractionated total body irradiation.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
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in the original EBR on this topic.
Comparison of Conditioning Regimens for
Allogeneic SCT
Marks et al. [35] compared the outcomes of pa-
tients (1-56 years) who underwent HLA-identical sib-
ling donor allogeneic peripheral blood stem cell
transplantation (PBSCT) or BMT for ALL in CR1
or CR2 after conditioning with cyclophosphamide
(Cy) 1 TBI (\13 Gy or $13 Gy) versus etoposide
(VP16) 1 TBI (\13 Gy or $13 Gy). Although not
all patients were pediatric, the median age for 3 of
the 4 treatment groups was #18 years. For patients
in CR1, there were no significant differences in 5-
year LFS or OS by conditioning regimen. For patients
in CR2, 5-year LFS and OS were significantly im-
proved with the etoposide-based regimen or with
TBI doses $13 Gy. Transplant-related mortality
(TRM) did not differ by conditioning regimen for ei-
ther disease status.
Gassas et al. [36] reported no significant differ-
ences by conditioning regimen in 3-year EFS, OS, or
TRM for pediatric patients with ALL (majority in
CR2/3) from a single center who underwent either
MRD or MUD allogeneic SCT after conditioning
with Cy 1 TBI (1200 cGy in 6 fractions) versus
VP16 1 TBI (1200 cGy in 6 fractions).
There were 3 high-quality studies (11 to 211)
that were used to make a treatment recommendation
regarding conditioning regimens in the original pedi-
atric ALL EBR. A randomized trial by Bunin et al.
[37] reported a significant improvement in 3-year
EFS and TRM, but not OS, in pediatric patients
with ALL who received Cy 1 VP16 1 TBI versus
those who received Cy 1 VP16 1 busulfan (Bu) as
conditioning before allogeneic SCT. Davies et al.
[38] reported significantly better 3-year LFS and OS
in pediatric patients with ALL who received Cy 1
TBI versus Cy1 Bu as conditioning before allogeneic
BMT. In a single-center study by Weisdorf et al. [39],
no significant difference was reported in 5-year DFS
among pediatric patients with ALL who received
Cy 1 TBI, Cy 1 fractionated TBI, or cytarabine 1
TBI as conditioning before allogeneic BMT.NONCOMPARATIVE STUDIES OF
TRANSPLANT FOR PEDIATRIC ALL
There were 14 noncomparative cohort studies
[40-53] published since the original EBR, which
examined the use of SCT as therapy for pediatric
ALL. The design, methodology, and outcomes data
from these noncomparative studies are summarized
in Appendix B (online only). The studies represent non-
randomized single or multi-institutional experiences
with various transplantation techniques or retrospectiveanalyses of transplantation registry data. The quality of
the noncomparative allogeneic SCT studies ranged
from 211 to 21; the quality of the autologous SCT
study was 21. Collectively, the outcomes data from
these studies contribute to the overall understanding
of the effectiveness of various transplantation tech-
niques for the treatment of pediatric ALL.
AREAS OF NEEDED RESEARCH AND
ONGOING STUDIES
After reviewing the updated evidence on the use of
SCT for pediatric ALL, the expert panel identified the
following important areas of needed research:
1. Reevaluate allogeneic SCT versus intensive che-
motherapy regimens in the current era, as both ap-
proaches have changed. Comparative studies
should be performed using methodology that
avoids bias.
2. Investigate the role and potential benefit of mater-
nal antigen microchimerism to reduce the risk of
graft-versus-host disease and enhance the graft-
versus-leukemia effect after allogeneic BMT.
3. Identify and address the treatment of high-risk
T-lineage ALL subsets.
4. Reevaluate the promising early studies of imatinib
in combination with chemotherapy or SCT for
Ph1 ALL in larger studies.
5. Investigate the optimal treatment for patients who
are persistently positive forminimal residual disease.
6. Improve the detection and monitoring of MRD
during initial treatment to guide individual patient
eligibility and timing of allogeneic SCT.
7. Monitoring MRD after SCT to detect early post-
SCT relapse in need of preemptive therapy.
8. Investigate the indications for using reduced in-
tensity versus myeloablative conditioning regi-
mens for allogeneic SCT.
9. Determine conditioning regimens that reduce or
eliminate the need for TBI while maintaining
effectiveness for ALL.
10. Investigate the prognostic role of initial risk classi-
fication (NCI SR/HR assignment) on outcomes
after relapse.
11. Investigate whether allogeneic SCT performed in
CR1 patients identified as very high risk for re-
lapse by molecular methods (ie, specific gene mu-
tations, gene expression profiles, etc.) improves
outcome compared to chemotherapy.
12. Investigate the impact of psychosocial support and
shared decision-making models to assist families
in weighing the risks versus benefits of SCT for
their children with ALL.
Ongoing Studies
There are new trials and ongoing studies on the
treatment of pediatric ALL that are accruing patients,
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stract form. These studies were not used as evidence
for the review or for making treatment recommenda-
tions. This section is provided for the reader’s infor-
mation only.
Rives et al. [54] described the results of the Spanish
Cooperative Group SHOP/SEHOP studies, which in-
vestigated intermediate dose imatinib given in combina-
tionwith intensive chemotherapy (SHOP05) compared
to no imatinib use (SHOP 94/99), followed by alloge-
neic SCT for patients with Ph1 ALL in CR1. This
study addresses Area of Needed Research #4. Median
follow-up for the SHOP 94/99 and SHOP 05 trials
was 113 and 30 months, respectively. The clinical out-
comes of interest were EFS and OS at 30 months.
Although not intended to guide patient eligibility
or timing of allogeneic SCT, a retrospective study by
Ruggeri et al. [55] on behalf of the Eurocord-EBMT
and EBMT-PDWP investigated the prognostic signif-
icance of beingMRD positive or negative before unre-
lated cord blood transplantation after a myeloablative
conditioning regimen. This study addresses Area of
Needed Research #6. Of 316 children and adolescents
with ALL in $CR1, 170 had MRD assessments; 74
positive and 96 negative. The median follow-up was
46 months (4-104 months), and the clinical outcomes
of interest were 4-year LFS, non-relapse mortality
and relapse.
Following are several ongoing pediatric ALL stud-
ies that do not relate specifically to any of the areas of
needed research suggested by the expert panel.
Myeloablative Related versus Unrelated SCT for
Relapsed ALL
Tracey et al. [56] examined the impact of condi-
tioning regimen and donor source on outcomes in
children and adolescents with ALL in $CR2 (90%)
or active relapse (10%). TBI dosing (\13 Gy versus
$13 Gy) or the addition of etoposide to a TBI 1 Cy
regimen was examined in 765 children who received
either an HLA-matched sibling (n 5 160) or unre-
lated donor (n 5 605) SCT.
Cord Blood Transplantation
A clinical trial (NCT00861679) sponsored by the
Hadassah Medical Organization is currently accruing
patients #18 years with ALL to compare HLA-
matched sibling or other matched donor versus
HLA-mismatched family or unrelated donor cord
blood transplantation versus a historical control of
chemotherapy only. The estimated enrollment is 552
patients, and the primary outcomes of interest are
EFS and OS.
A phase III, randomized, prospective clinical trial
(NCT00412360) sponsored by the National Heart,
Lung, and Blood Institute, in collaboration with theBlood and Marrow Transplant Clinical Trials Net-
work and National Cancer Institute, compares single
versus double cord transplantation for patients 1 to
21 years of age with high-risk leukemia, including
ALL, or myelodysplasia. The estimated enrollment is
220 patients, and the primary outcomes of interest
are 1-year OS and TRM.
Intensive Chemotherapy and Early SCT for MLL
Koh et al. [57] reported the results of a Japanese Pe-
diatricLeukemia/LymphomaStudyGroupmulticenter,
nonrandomized trial (MLL03) of infants\12 months
with ALL 1MLL gene rearrangement to test the effi-
cacy of intensive chemotherapy followed by SCT #4
months after achieving CR1. Conditioning regimen
was Bu and Cy. Of 63 registered patients, 49 achieved
CR1, and 44underwent SCT fromunrelated cord blood
(n 5 32) or a related donor (n 5 11; 1 unknown).
STRENGTHS/LIMITATIONS AND
DISCUSSION
The strengths of this updated systematic evidence-
based review are the details about each study’s design
and outcomes conveyed in the summary tables for
each major section, and the treatment recommenda-
tions made by the pediatric ALL expert panel. The
reader is directed to Appendix A, which describes the
methodology of this systematic evidence-based review.
Of note, the treatment recommendations are reached
by consensus of the expert panel based on the evidence
included in the tables of this review. A different panel
constitution (as well as the reader) may yield a different
treatment recommendation, especially in areas with
little or no data. Hence, the data are presented in an
objective, nonjudgmental format with enough detail
so the reader can assess the value of the evidence and
the treatment recommendations.
A limitation of this review is the exclusion of non-
peer-revieweddata.Many studieswith negative findings
go unpublished or are published as non-peer-reviewed
abstracts, while those with positive findings are pub-
lished as full research articles, which can lead to publica-
tion bias. However, the inclusion of high-quality,
peer-reviewed, publicly available data was of param-
ount importance for this review. Except in the Ongoing
Studies section, data published in abstract formwerenot
included in this review due to the inadequate details of
study design or patient characteristics, making a true as-
sessmentof thewidespreadapplicability or impact of the
treatment outside the scope of the trial difficult.
The quality of this systematic EBR is affected by
treatment modalities, which vary over time. Chemo-
therapy regimens, HLA typing techniques, novel pre
and post-SCT biologic and TKI therapies, and post-
SCT supportive care change considerably over the
course of these reviews and updates. The clinical
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these studies outmoded by the time of publication.
Much of the newly presented data may not reflect
current practice or represents preliminary results
from small studies, stressing the need for faster conduct
of well-designed studies, shorter accrual times, and
swift analysis and publication of research. In addition,
the lengthy process of conducting and reporting clini-
cal research emphasizes the need to identify surrogate
endpoints or molecular markers that are predictive of
long-term survival in pediatric patients with ALL.
Further delineation of clinical risk factorsmay facilitate
appropriate selection of patients with ALL for SCT.
Comparative studies of chemotherapy and SCT
are very difficult to conduct and interpret. Many stud-
ies with randomized designs have failed to meet
accrual objectives or failed to deliver therapy as in-
tended, resulting in special issues that should be con-
sidered when comparing chemotherapy with SCT.
These issues include the following:
 Analyses should be either from attainment of CR or
only include those who attain CR. Include only pa-
tients who received a transplantation who were in
remission and chemotherapy patients who maintain
remission until median time to SCT.
 High-risk groups should be analyzed separately. If
a risk factor (eg, MLL) means poor prognosis in
one group (eg, infants \6 months with high
WBC) and prognosis above 60% in other groups
(eg, older infants and children with ALL), any ben-
eficial effect of one treatment group over another is
masked if high and low-risk patients are pooled.
Meta-analysis of individual patient level data should
be considered if specific studies are of insufficient
size to answer the subgroup questions.
 Appropriate statistical methods, explicit study defi-
nitions, and clear exclusion/inclusion criteria should
be used and reported. It is essential that studies also
report hematopoietic cell source, the approach, tim-
ing and eligibility for SCT, and the preparatory and
conditioning regimens used.
 Era-appropriate, high-quality chemotherapy should
be used in the chemotherapy cohort.
Despite, and due to these challenges, it is of utmost
importance that childrenwithALLbeenrolled inongo-
ing clinical studies to better understand the role of SCT
in their therapy.Thedecision to utilize SCT in children
with ALL should be made by the patient (when possi-
ble), the family/guardians, and an interdisciplinary
team of providers with full consideration of both the
clinical and psychosocial risks versus benefits involved,
including possible late and long-term effects of treat-
ment. Shared decision-making models (in which both
the provider and the patient/family share their views
of uncertainty, their own risk/benefit consideration,and their expectations of outcome), should be consid-
ered in clinical trial enrollment strategies and follow-
up plans, along with short and long-term psychosocial
assessment and support for the patient and family.ACKNOWLEDGMENTS
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